-
Mashup Score: 1FDA extends Vemlidy approval for chronic hepatitis B to children as young as 6 years - 1 month(s) ago
The FDA has updated the label indication for Vemlidy 25 mg for the treatment of chronic hepatitis B virus with compensated liver disease, expanding the patient population to include children aged 6 years and older who weigh at least 25 kg. Vemlidy (tenofovir alafenamide, Gilead Sciences) — a nucleoside analog reverse transcriptase inhibitor — was previously approved for the adult
Source: www.healio.comCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 2FDA extends Vemlidy approval for chronic hepatitis B to children as young as 6 years - 1 month(s) ago
The FDA has updated the label indication for Vemlidy 25 mg for the treatment of chronic hepatitis B virus with compensated liver disease, expanding the patient population to include children aged 6 years and older who weigh at least 25 kg. Vemlidy (tenofovir alafenamide, Gilead Sciences) — a nucleoside analog reverse transcriptase inhibitor — was previously approved for the adult
Source: www.healio.comCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 2FDA extends Vemlidy approval for chronic hepatitis B to children as young as 6 years - 1 month(s) ago
The FDA has updated the label indication for Vemlidy 25 mg for the treatment of chronic hepatitis B virus with compensated liver disease, expanding the patient population to include children aged 6 years and older who weigh at least 25 kg. Vemlidy (tenofovir alafenamide, Gilead Sciences) — a nucleoside analog reverse transcriptase inhibitor — was previously approved for the adult
Source: www.healio.comCategories: General Medicine News, GastroenterologyTweet
🚨BREAKING🚨 @US_FDA updated the label indication for #Vemlidy 25 mg for the treatment of chronic #HBV 🦠 with compensated #liverdisease, expanding the patient population to include children aged 6 years and older who weigh at least 25 kg. Learn more 🔽 https://t.co/cCYBjgL90W